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lization and outcomes. Each factor was rated by three independent reviewers on a 
scale from 1 to 5, with 1 being limited use in economic modeling and 5 being highly 
useful for health economic modeling. Ratings were summed for each reviewer and 
averaged to produce a score out of 20 possible points. Results: Of the 14 real-world 
data sets assessed for utility in health economic modeling, claims data rated highest 
(15 out of 20) due to the availability of patient-level data from multiple sites of care, 
but lacked a link between utilization and patient outcomes. Despite the availability 
of patient outcomes associated with utilization with EMR data, the data set was rated 
the lowest (8 out of 20) due to its lack of nationally representative data and proprietary 
access. ConClusions: Of the currently available real-world data sets, claims data 
was viewed as most useful for health economic models because they include patient-
level utilization data from multiple sites of care. Data mined from EMR represents 
a significant opportunity to link healthcare utilization with patient outcomes, but 
currently available EMR data lacks national representation and is expensive to obtain.
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objeCtives: As more psoriasis treatments come to market in both new and exist-
ing drug classes, health care payers will need assistance in determining the most 
cost-effective regimen or sequence of regimens to control budgets. We sought to 
devise a cost-effectiveness modeling structure that will aid in decision making by 
highlighting differentiating factors between drugs and meet the changing needs of 
payers. Methods: A systematic literature review was conducted to identify previ-
ously published cost-effectiveness models in moderate to severe psoriasis. As part of 
this review, we identified manufacturer submissions to health technology assessment 
(HTA) bodies and HTA responses/critiques of the submissions. The review showed that 
many previous models focused on one line of biologic therapy followed by standard of 
care. Additionally, Psoriasis Area Severity Index (PASI) response was limited in respect 
to both time periods considered and the categories of response modeled. Results: 
We developed a model structure that expanded the treatment/modeling paradigm by 
allowing a sequence of therapies (two lines of biologic therapies followed by standard 
of care). A short-term decision tree allows for a clinical determination of PASI response 
at 12 or 16 weeks post-initiation of therapy. Within the initial 12 or 16 week treatment 
period, we model the change in PASI levels over time to better reflect quality-of-life 
for patients on treatments with better speed of response. Following the decision tree, 
patients enter a semi-Markov (semi-Markov due to time dependent death probabili-
ties) to estimate long-term costs and outcomes. As new drugs allow some patients 
to achieve complete psoriasis clearance, we included a PASI 100 health state. Finally, 
we model disutilities related to severe adverse events to distinguish drugs with bet-
ter safety profiles. ConClusions: This new framework will help decision makers 
by better differentiating psoriasis treatments and determining the optimum order 
of biologic therapies in the psoriasis treatment pathway.
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objeCtives: To calculate national estimates of Necrotizing Enterocolitis (NEC)–
related hospitalization and associated use of health care resources to explore the 
effects of certain patient and hospital characteristics on use of hospital resources 
and length of stay in the United States. Methods: Data from the 2009 Healthcare 
Cost and Utilization Project Kids’ Inpatient Database was used. Pediatric inpatient 
care in 4121 hospitals in 44 US states. Inpatient admissions with an International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of 
Necrotizing Enterocolitis. National estimates of NEC-associated hospitalizations 
were calculated. Potentially significant covariate associations were studied using 
hospital costs and Lengths of Stay as dependent variables. Predictors of high hos-
pitalization cost and prolonged length of stay were evaluated using multivariable 
logistic regression. Results: 2203 NEC-related hospitalizations occurred among 
infants in the United States in 2009, resulting in more than $213 Million in inpa-
tient hospitalization costs. Mean hospital costs and LOS were $110,951 and 51 days, 
respectively. Treatment type, died or not during hospitalization, comorbidities, 
complications, hospital type and hospital region, were significantly associated 
with higher total costs and longer length of stay. ConClusions: For an infant 
disease with a rather low prevalence rate, the estimated annual inpatient pedi-
atric burden of NEC is a sizeable $213.3 million (2009 US$). As surgery treatment 
significantly influenced cost and length of hospitalization, there is an opportunity 
for reduction in inpatient burden if medications and outpatient treatments would 
improve for the treatment of NEC.
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objeCtives: The burden of disease due to seasonal influenza in the United States 
(US) remains high, despite vaccination efforts. In 2003 it was estimated that the 
direct medical costs averaged $10.4 billion, with a total economic burden estimated 
at $87.1 billion. Although the seasonal influenza vaccination is not always a con-
summate match, we suggest that the burden of disease is still greatly reduced 
even when vaccine match to circulating strain is suboptimal. This study aims to 
examine the decreased cost burden associated with the seasonal influenza vaccine, 
even in seasons of suboptimal match, by comparing historic published trends to 
large claims data. Methods: Previously published data were compared to sea-
sonal influenza records, queried from a claims database containing over 55 million 
unique patients. Regression modeling was used to compare cost burden of persons 
and 0.0032 for obese men. Using overweight men as an example, the risk of death in 
this group was higher for diabetics than non-diabetics and increased with age and 
BMI. ConClusions: Our results showed that women had a higher risk of diabetes 
but a lower risk of death for both diabetics and non-diabetics than men. Moreover, 
both risks increased with BMI and age. This joint estimation of the transition prob-
abilities in the Markov model overcomes the problem of negative probabilities 
resulting from separate estimations.
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objeCtives: To develop quality of care (QC) metrics using claims data in hepatitis 
C (HCV) Medicare patients with disability, a vulnerable population facing increased 
access barriers and representing the majority of HCV patients in Medicare, and 
quantify metrics’ correlation with treatment receipt. Methods: We adapted 14 
Veterans Affairs-developed quality metrics (QM) for measurement in a cohort 
of 1,936 disabled HCV patients (2006-2009) with 6 months continuous Medicare 
parts A, B, D enrollment before diagnosis and no previous treatment. Based on 
the machine-learning principle of recursive partitioning, the proposed algorithm 
implements a random forest model of conditional inference trees, identifies the for-
est’s representative tree, and aggregates its terminal nodes into QC patient groups. 
Using linked county-level data from the Area Health Resource Files, we compared 
contextual characteristics across QC groups. Results: On average, 10.4% received 
peg-interferon. The five strongest predictors of treatment included “having received 
liver biopsy”, “HCV genotype testing”, “visit to specialist”, “confirmation of HCV 
viremia”, and “iron overload testing”. High QC (n= 360; treated= 33.3%) was defined 
for patients who had at least 2 from the abovementioned metrics. Good QC patients 
(n= 302; treated= 12.3%) had either “HCV genotype testing” or “visit to specialist”, 
while fair QC patients (n= 282; treated= 7.1%) only had “confirmation of viremia”. 
Patients with low QC (n= 992; treated= 2.5%) had none of the selected QMs. The 
algorithm accuracy of predicting treatment was 70% sensitivity and 78% specificity. 
Compared to those with fair or low QC, more high and good QC patients lived in rural 
or small town areas with lower access to specialized hospital and physician services 
and lower rates of insurance and education. ConClusions: Higher quality of care 
correlated with higher treatment rates. Limited healthcare access among Medicare 
disabled patients with HCV was not associated with lower quality. Future research 
is needed to assess pre-treatment QM with newer HCV therapies.
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objeCtives: Polymorphism of CYP2C19 affects metabolism and drug response of 
clopidogrel. New antiplatelet drugs such as prasugrel and ticagrelor are not affected 
by CYP2C19 polymorphism. CYP2C19 genetic testing could guide the selection of 
clopidogrel versus new antiplatelet agent (genotype-guided therapy). Published 
cost-effectiveness analyses of universal prasugrel or ticagrelor treatment versus 
genotype-guided therapy for patients with acute coronary syndrome (ACS) and 
planned percutaneous coronary intervention (PCI) yet showed conflicting results. 
We aimed to evaluate the cost-effectiveness of the new class of antiplatelet drugs 
versus genotype-guided therapy. Methods: A lifelong Markov model was devel-
oped to compare universal new antiplatelet drugs treatment and genotype-guided 
therapy from the perspective of healthcare provider. In genotype-guided therapy 
arm, patients without CYP2C19 loss-of-function (LOF) allele would receive generic 
clopidogrel, while patients with at least one LOF allele would receive a new anti-
platelet agent. All clinical inputs were derived from published meta-analysis and 
clinical trials. Direct medical costs and quality-adjusted life-year (QALY) gained were 
the primary model outcomes. Results: Base-case results showed that genotype-
guided therapy cost $73,131 with 8.068 QALYs, while universal new antiplatelet 
therapy cost $79,179 with 7.946 QALYs. With a threshold of willingness-to-pay of 
$50,000 per QALY, no threshold values were identified in one-way sensitivity analy-
sis. The most influential factor was the probability of ischemic heart disease (IHD) 
state turned to death, followed by the possibility of post myocardial infarction state 
turned to death, cost of PCI and utility of IHD. In probabilistic sensitivity analysis, 
genotype-guided therapy was dominant with $6192 (95% CI 6170-6214) less costly 
and a gain of 0.2235 QALY (95% CI 0.2234-0.2236) compared with universal new anti-
platelet therapy. ConClusions: Compared with universal use of new antiplatelet 
drugs, genotype-guided therapy seems to be a less costly and more effective clinical 
strategy for patients with ACS undergoing PCI.
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objeCtives: Effective and robust health economic models are built on a foundation 
of reliable, accurate data sets. With the availability of various real-world data sets, 
the objective of this study was to examine several real-world data sets and rate their 
overall utility for use in health economic models in the United States. Methods: 
Real-world data sets included in the assessment were one claims dataset, one elec-
tronic medical record (EMR) dataset, 11 state-level all payer claims databases (APCDs) 
and data from the Healthcare Cost and Utilization Project (HCUP). Factors assessed 
included: coverage of national versus regional population, inclusion of various sites 
of care, free/public access, and availability of longitudinal patient-level data on uti-
